Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: ValuEngine, Inc.
Provider: Finlabo SIM Spa

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Grifols SA Signs Deal To License Aradigm Corp's Pulmaquin; May Buy 35% Stake In Aradigm Corp-Reuters

Tuesday, 21 May 2013 02:47am EDT 

Reuters reported that Grifols SA said it has signed an exclusive contract to license Aradigm Corp's Pulmaquin compound and may take a stake in the California-based firm. Pulmaquin is a dual release ciprofloxacin for inhalation in non-cystic fibrosis bronchiectasis. In a regulatory filing, Grifols SA said it will invest up to USD 65 million to help develop the compound and may spend USD 25.7 million to buy a 35% stake in Aradigm Corp through a capital hike at the United States firm. 

Company Quote

1.04 +2.85%
11:11am EST